Reunion Neuroscience
Reunion Neuroscience is a clinical-stage biopharmaceutical company developing psychedelic-inspired neurotherapeutics — led by luvesilocin (RE104) — for postpartum depression, adjustment disorder, and generalized anxiety disorder, with FDA Breakthrough Therapy Designation and a planned Phase 3 trial in 2026.
- Company typePrivate
- Founded2019
- HeadquartersToronto, Canada
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Reunion Neuroscience does
Reunion Neuroscience is a clinical-stage biopharmaceutical company developing psychedelic-inspired neurotherapeutics for underserved mental health conditions. The company's lead candidate, luvesilocin (RE104), is being advanced across multiple neuropsychiatric indications — postpartum depression, adjustment disorder, and generalized anxiety disorder — with an FDA Breakthrough Therapy Designation granted in February 2026 for the postpartum depression program on the basis of positive Phase 2 RECONNECT data showing a 23.0-point reduction in MADRS depression score at Day 7 (p=0.0094) with effects observed as early as Day 1 and sustained through 28-day follow-up. A second pipeline candidate, RE245, has an IND filing planned for 2026, indicating active portfolio diversification beyond the lead asset.
The company's core technology centers on proprietary psychedelic-inspired drug design intended to deliver rapid antidepressant and anxiolytic efficacy with a short psychoactive experience, differentiated from conventional SSRIs that require weeks of dosing. Luvesilocin's profile — rapid onset combined with durability — is positioned against the unmet need for fast-acting treatments in postpartum depression and related indications. The company has completed an End of Phase 2 meeting with FDA, aligned on the registrational path, and plans to initiate a pivotal Phase 3 trial in 2026.
Reunion Neuroscience is pre-revenue and funds operations through equity capital, most recently closing a $133 million Series A financing in September 2025 led by MPM Capital and Novo Holdings, with participation from Arkin Bio Ventures, FemHealth Ventures, Mitsui Global Investment, Palo Santo Fund, and Plaisance Capital Management. The company intends to generate revenue through prescription pharmaceutical sales following FDA approval, distributing via specialty pharmacies, hospitals, and healthcare providers, and has not disclosed any active out-licensing or partnership economics. Leadership transitioned in June 2026 with the appointment of Dr. Sahil V. Kirpekar, M.D., as President, CEO, and Board Member, bringing experience from atai Life Sciences and Otsuka Pharmaceutical relevant to late-stage clinical execution and potential strategic transactions.
Reunion Neuroscience firmographics
Firmographics- Name
- Reunion Neuroscience
- Legal name
- Reunion Neuroscience
- Website
- https://reunionneuro.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Reunion Neuroscience is a clinical-stage biopharmaceutical company developing psychedelic-inspired neurotherapeutics — led by luvesilocin (RE104) — for postpartum depression, adjustment disorder, and generalized anxiety disorder, with FDA Breakthrough Therapy Designation and a planned Phase 3 trial in 2026.
- Ownership category
- akta.pro rank
Reunion Neuroscience industry classification
Industry- Product category
- Neuropsychiatric Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)
- akta.pro secondary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Reunion Neuroscience is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Reunion Neuroscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Pharmaceutical Product Revenue: Pre-revenue clinical-stage biotech company. Once drugs receive FDA approval, revenue will be generated through prescription pharmaceutical sales. The company is developing luvesilocin for postpartum depression with Breakthrough Therapy Designation accelerating the regulatory path.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Reunion Neuroscience product offering
Product offeringCore offering
Reunion Neuroscience is a clinical-stage biopharmaceutical company developing psychedelic-inspired neurotherapeutics for underserved mental health conditions. Its lead candidate, luvesilocin (RE104), is being advanced through clinical trials for postpartum depression, adjustment disorder, and generalized anxiety disorder, and has received FDA Breakthrough Therapy Designation for postpartum depression. A second pipeline candidate, RE245, is planned for IND filing in 2026.
Product overview
Reunion Neuroscience is a clinical-stage biopharmaceutical company developing novel therapies for mental health conditions. The company's lead product is luvesilocin (RE104), a psychedelic-inspired therapeutic currently in Phase 2/3 development for postpartum depression, adjustment disorder, and generalized anxiety disorder. The company also has RE245 in its pipeline with an IND filing planned for 2026. The company completed a $133 million Series A financing to advance clinical development.
Differentiator
Problem solved
Functional benefit
Products and services
- Luvesilocin (RE104) Psychedelic-inspired neurotherapeutic in development as a prescription pharmaceutical for postpartum depression, adjustment disorder, and generalized anxiety disorder. Demonstrated a 23.0-point reduction in MADRS depression scale at Day 7 with 30mg dose (p=0.0094) in the Phase 2 RECONNECT trial in 84 adult female patients with moderate-to-severe postpartum depression, with effects observed as early as Day 1 and maintained through 28-day follow-up.
- RE245 Investigational neuropsychiatric drug candidate intended to expand Reunion's pipeline beyond luvesilocin. IND filing planned for 2026.
Quantifiable outcome
- 23.0-point reduction in MADRS depression scale at Day 7 with 30mg dose (p=0.0094)
- +1 more outcomes
Companies that use Reunion Neuroscience
Customer profileSegments3 records
Ideal customer profiles1 record
Reunion Neuroscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Reunion Neuroscience partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights5 records
Reunion Neuroscience competitors and assessment
Company assessmentBroad incumbents
- Otsuka Pharmaceutical: Global CNS biopharma (developer of Abilify) and former employer of Reunion's new CEO. Large incumbent with established CNS commercial infrastructure relevant as a potential strategic partner for luvesilocin.
- Biogen: Large CNS-focused biopharmaceutical company that partnered with Sage Therapeutics on Zurzuvae/zuranolone for PPD. Broad incumbent with overlapping CNS franchise and commercial PPD presence that creates partnership and competitive overlap with Reunion.
- Jazz Pharmaceuticals: Specialty CNS biopharma with franchises in epilepsy, psychiatry, and sleep. Broad incumbent in CNS specialty pharma that could compete for or partner on rapid-acting PPD/psychiatric assets.
Direct peers
- Sage Therapeutics: Developer of Zurzuvae (zuranolone) and Zulresso, the first FDA-approved therapies specifically for postpartum depression. Most directly comparable peer given same indication (PPD) and CNS specialty pharma model, though Sage is more advanced commercially.
- Compass Pathways: Clinical-stage company developing psilocybin therapy for treatment-resistant depression, with Breakthrough Therapy Designation. Direct peer in psychedelic-inspired CNS drug development targeting depression.
- MindMed: Clinical-stage psychedelic medicine company developing MM-120 (lysergide) for anxiety disorders and other CNS indications. Direct peer in psychedelic-inspired therapeutics for anxiety and depression.
- Atai Life Sciences: Clinical-stage biopharma developing psychedelic and psychedelic-inspired therapies for mental health, including depression and anxiety. Direct peer in psychedelic-inspired CNS development; also Reunion's incoming CEO's prior employer.
- GH Research: Clinical-stage company developing mebufotenin and other psychedelic-based therapies for treatment-resistant depression. Direct peer in psychedelic drug development for CNS indications.
- Cybin: Clinical-stage company developing deuterated psychedelic compounds (e.g., CYB003) for depression and other psychiatric conditions. Direct peer in psychedelic-inspired CNS therapeutics.
Emerging players
- Neumora Therapeutics: Clinical-stage neuroscience company developing precision medicines for brain diseases including depression. Emerging player with overlapping CNS pipeline and similar Series-stage development profile.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Reunion Neuroscience social profiles
Digital presenceReunion Neuroscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Reunion Neuroscience leadership team
Management profileNumber of profiles
Profiles3 records
Reunion Neuroscience funding detail
Funding detailFunding overview
Funding rounds1 record
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Reunion Neuroscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Reunion Neuroscience
What does Reunion Neuroscience do?
Reunion Neuroscience is a clinical-stage biopharmaceutical company developing psychedelic-inspired neurotherapeutics for underserved mental health conditions. Its lead candidate, luvesilocin (RE104), is being advanced through clinical trials for postpartum depression, adjustment disorder, and generalized anxiety disorder, and has received FDA Breakthrough Therapy Designation for postpartum depression. A second pipeline candidate, RE245, is planned for IND filing in 2026.
Is Reunion Neuroscience a public or private company?
Reunion Neuroscience is a private company. It is classified as venture growth investor backed and is currently operating.
When was Reunion Neuroscience founded?
Reunion Neuroscience was founded in 2019. It employs 1 to 10 people.
Where is Reunion Neuroscience based?
Reunion Neuroscience is headquartered in Toronto, Canada, in the North America region.
How does Reunion Neuroscience make money?
One revenue line is on record: pharmaceutical Product Revenue.
Who are Reunion Neuroscience's main competitors?
Broad incumbents on record are Otsuka Pharmaceutical, Biogen and Jazz Pharmaceuticals. Direct peers are Sage Therapeutics, Compass Pathways, MindMed, Atai Life Sciences, GH Research and Cybin. Neumora Therapeutics is listed as an emerging player.
Does Reunion Neuroscience have an API?
No public API is recorded for Reunion Neuroscience.
What industry is Reunion Neuroscience in?
Reunion Neuroscience's product category is Neuropsychiatric Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8071.